CFO Radhakrishnan Karthik bought 1,550 shares of MNPR at $16.25 on 2024-10-28 ($25.2K); first purchase for CFO amid unprofitable operations and volatile equity price.
Radhakrishnan Karthik, Chief Financial Officer of Monopar Therapeutics, initiated his first equity stake in the company with a purchase of 1,550 shares at $16.25, bringing his post-transaction holdings to 1,550 shares from zero. The timing is notable: the purchase was made at a price $1.58 above the current market price of $14.67, and at 49.8% of the 52-week high of $32.66, reflecting substantial price decline from peak levels. The stock has experienced extreme volatility—trading -55.1% below its 52-week high while gaining +117.7% over the past 30 days and +323.2% over the past 90 days—suggesting acute near-term fluctuation rather than fundamental stability. Against this backdrop, the CFO's first personal equity purchase is material for governance scrutiny, particularly given that Monopar Therapeutics is currently unprofitable with a net income of $-1.7M and zero revenue in the latest quarter, conditions that typically warrant caution from financial leadership before deploying personal capital.